Last Updated: 2026

Galectin Therapeutics

Rank#9021

Market Cap149.43M

CountryUnited States

Summary

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

History

Galectin Therapeutics was founded in 2000 and has been focused on developing therapeutics that target galectin proteins to treat a variety of diseases. The company has developed two clinical stage drugs, Gelareol® and GR-MD-02, that target galectin proteins to treat liver fibrosis, cancer and other disorders.

Mission

Our mission is to develop unique and innovative therapeutics based on our unique understanding of galectin proteins. We strive to improve the lives of patients by developing products that improve their quality of life.

Vision

Our vision is to become a leader in the development of galectin-based therapeutics for the treatment of cancer, fibrotic diseases, and other disorders.

References

https://in.investing.com/equities/galectin-therapeutics-inc-unit

https://finance.yahoo.com/quote/GALT/profile?p=GALT

https://www.crunchbase.com/organization/pro-pharmaceuticals

https://companiesmarketcap.com/

https://galectintherapeutics.com

Leadership team

Mr. Joel Lewis (Pres, CEO & Director)

Dr. Pol F. Boudes M.D., Ph.D. (Chief Medical Officer)

Mr. Jack W. Callicutt CPA, CPA (CFO, Treasurer & Corp. Sec.)

Products / Services

Biopharma, Biotechnology, Health Care, Pharmaceutical

Address

Norcross, Georgia, United States

Established

2000-01-01

Company Registration

SEC CIK number: 0001133416

Traded as

GALT

Website

https://galectintherapeutics.com

Social Media

Last Updated: 2026

Galectin Therapeutics

Rank#9021

Market Cap149.43M

CountryUnited States

Summary

History

Mission

Vision

Our vision is to become a leader in the development of galectin-based therapeutics for the treatment of cancer, fibrotic diseases, and other disorders.

References

https://in.investing.com/equities/galectin-therapeutics-inc-unit

https://finance.yahoo.com/quote/GALT/profile?p=GALT

https://www.crunchbase.com/organization/pro-pharmaceuticals

https://companiesmarketcap.com/

https://galectintherapeutics.com

Leadership team

Mr. Joel Lewis (Pres, CEO & Director)

Dr. Pol F. Boudes M.D., Ph.D. (Chief Medical Officer)

Mr. Jack W. Callicutt CPA, CPA (CFO, Treasurer & Corp. Sec.)

Products / Services

Biopharma, Biotechnology, Health Care, Pharmaceutical